TrialAdvances in therapy2026

Post Hoc Subgroup and Body Region Analyses of VASI Outcomes Among Patients with Vitiligo in a Phase 2 Povorcitinib Trial.

Thierry Passeron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.